The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study.
Michael Ewer
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Genentech (U)
José Baselga
Consultant or Advisory Role - Roche/Genentech
Emma Clark
Employment or Leadership Position - Roche
Stock Ownership - AstraZeneca
Mark Benyunes
Employment or Leadership Position - Genentech
Graham Ross
Employment or Leadership Position - Roche
Stock Ownership - Roche
Sandra M. Swain
Consultant or Advisory Role - Nektar (U); Novartis (U); Roche/Genentech (U); Sanofi (U)
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech; Sanofi
Other Remuneration - Sanofi